We came across a bearish thesis on Capricor Therapeutics, Inc. on Alpha Talon Investment Research’s Substack by AT Investment Research. In this article, we will summarize the bulls’ thesis on CAPR. Capricor Therapeutics, Inc.'s share was trading at $26.55 as of December 15th.
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, develops transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. CAPR remains a structurally challenged, chronically unprofitable...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.